CSIMarket
 
Organogenesis Holdings Inc   (ORGO)
Other Ticker:  
 
 
Price: $2.7500 $-0.10 -3.509%
Day's High: $2.975 Week Perf: -6.46 %
Day's Low: $ 2.73 30 Day Perf: -25.27 %
Volume (M): 830 52 Wk High: $ 4.71
Volume (M$): $ 2,283 52 Wk Avg: $3.05
Open: $2.87 52 Wk Low: $1.80



 Market Capitalization (Millions $) 367
 Shares Outstanding (Millions) 133
 Employees 896
 Revenues (TTM) (Millions $) 448
 Net Income (TTM) (Millions $) 12
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 32

Organogenesis Holdings Inc
Organogenesis Holdings Inc is a globally recognized healthcare company that operates in the regenerative medicine and biomaterials industries. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Organogenesis is committed to providing innovative solutions for wound healing, tissue regeneration, and surgical products that enhance the standard of care for patients globally.

Organogenesis Holdings focuses on developing products that are biologically-based and offer regenerative properties to promote healing and restoration of damaged tissues. The products developed by the company are based on advanced scientific research that integrates biological and physical factors to create a unique bioengineering product. The three main areas of focus for Organogenesis are Advanced Wound Care, Surgical & Sports Medicine, and Orthobiologics.

Advanced Wound Care is the primary focus of the company, and it offers an extensive product line to aid in the process of wound healing. The products developed for Advanced Wound Care include Apligraf, a bioengineered living cell product that aids in the healing of diabetic foot ulcers, venous leg ulcers, and pressure sores, and Dermagraft, a bioengineered dermal substitute that offers the ability to restore tissue for the treatment of chronic wounds.

Organogenesis Holdings aims to provide innovative surgical and sports medicine solutions for tissue repair, restoration, and healing. The company's products in this category include NuShield, a xenogenic tissue matrix that provides a barrier to soft tissue, and Allosync, a product that aids in the re-building of damaged cartilage.

Orthobiologics is a focus area of Organogenesis, and the company offers products that provide support and restoration for bone tissue. The products in this category include Gintuit, a product that is used for tissue regeneration and restoration, and NuCel, which is used for bone grafting and repair.

Organogenesis also places a great deal of focus on research and development to ensure that it remains at the forefront of the regenerative medicine industry. The company's R&D team is responsible for exploring new technologies and techniques that can be used to develop new products that offer better results to patients.

In conclusion, Organogenesis Holdings Inc is a leading healthcare company that is committed to research, development, and innovation in the regenerative medicine and biomaterials industries to ensure that it provides optimal solutions for tissue restoration and healing for patients globally.


   Company Address: 85 Dan Road Canton 2021 MA
   Company Phone Number: 575-0775   Stock Exchange / Ticker: NASDAQ ORGO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Organogenesis Holdings Inc

Organogenesis Holdings Inc Displays Consistent Earnings per Share in Q3 2023 Earnings Season



Organogenesis Holdings Inc has experienced significant stock gains in recent months. However, a closer look at its financial results for the third quarter of the 2023 earnings season reveals a mixed picture. While income per share remained stable, profit and revenue experienced substantial declines. This article aims to interpret the impact of these financial results on Organogenesis Holdings Inc going forward.
1. Stock Gain:
Over the last five trading days, the stock of Organogenesis Holdings Inc has gained an impressive 16.1%. Furthermore, the stock has surged by a staggering 44.23% over the past 90 days. Currently trading on NASDAQ, the stock is performing exceptionally well, trading 34% above its 52-week average. These gains indicate investor confidence in the company's future prospects.

Organogenesis Holdings Inc

Organogenesis Holdings Inc. Reports Decline in Revenue, but Surpasses EPS Expectations

Organogenesis Holdings Inc., a leading company in the Major Pharmaceutical Preparations sector, recently reported its financial results for the April to June 30, 2023 span. The earnings per share (EPS) for this period saw a significant decline of -42.86%, dropping to $0.04 per share compared to $0.07 per share in the same period the previous year. However, it is worth noting that the EPS turned positive from -$0.02 per share in the prior reporting season.
The revenue for Organogenesis Holdings Inc. also experienced a decrease of -3.365%, falling to $117.32 million from $121.40 million in the same reporting season a year prior. On a sequential basis, the revenue showed growth, advancing by 8.987% from $107.64 million. This decline in revenue is in contrast to the overall trend in the Major Pharmaceutical Preparations sector, which posted a 2.65% rise in top-line relative to the second quarter of 2022 in the second quarter of 2023.

Organogenesis Holdings Inc

Organogenesis Holdings Inc Faces Mounting Deficit Amid Challenging First Quarter of 2023

Organogenesis Holdings Inc is a biotech company specializing in regenerative medicine. However, their recent financial reports suggest that their ability to collect accounts receivable has been sequentially worsening, with their average receivable collection period increasing to 72 days in the March 2023 quarter, compared to 71 days in the previous quarter. This indicates a challenging and deteriorating business climate for the Major Pharmaceutical Preparations industry, which Organogenesis Holdings Inc is a part of.
Despite the overall decline in Organogenesis Holdings Inc's receivable turnover ratio, their total ranking has improved to 271 in the current quarter from the fourth quarter of 2022. When compared to other healthcare sector companies, there are some that have higher receivables turnover ratios.






 

Organogenesis Holdings Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com